Views & Analysis | Perspectives on pharma industry issues

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Patients

Union Jack on pill, one of many scattered on aqua surface

Rare diseases, real opportunity: Why the UK’s next challenge...

The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

Articles

Paediatrics: an unexplored and rewarding population – the ri...

As outcomes research becomes increasingly understood, and given the associated incentives could it be time to explore healthcare interventions in children? Linda Abetz-Webb explores... Many treatments with potential value in children have not been tested in paediatric populations. Incentives and penalties to encourage...

Articles

Social media and corporate influence: the case for a thought...

In a world where decisions are more likely to be made on the basis of a recommendation can pharma really influence what is being said about its brands in the social media space? What currently appears to be on the senior corporate executive mind is the question: “How can we, as a corporation, influence the social media debate about...

Articles

Emerging markets – the new gold rush? (part 1)

Amit Vaidya offers a guide to considerations and risks associated with entering emerging markets in the first of this three part series. The Pharmaceutical industry in common with many other sectors goes through what one might describe metaphorically as “fashionable change”. Examples might be...

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

Sales & Marketing

Sponsored

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Digital

Sponsored

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Market Access

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology